Issues
-
Cover Image
Cover Image
Fluorescence in-situ hybridization (FISH) analysis using an ERG break-apart probe in LNCaP prostate cancer cells with three copies of chromosome 21. The intact ERG loci at 21q22.3 is shown by three pairs of adjacent red and green FISH signals, corresponding to the 5′ and 3′ ends of the ERG gene, per blue cell nucleus. ERG rearrangement, as indicated by separate red and green FISH signals, resulting from intragenic breakage and translocation of part of the ERG gene in the cell nucleus at the bottom of the picture, was induced by treating the cells with doxorubicin and dihydrotestosterone. Inactivation of chromodomain helicase DNA-binding protein 1 (CHD1) by genomic deletion of its gene locus at chromosome 5q21 attenuates androgen receptor (AR) signaling and impairs formation of AR-dependent ERG rearrangements in prostate cancer. For details, see article by Burkhardt and colleagues on page 2795. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
Perspective
Priority Report
Clinical Studies
Integrated Systems and Technologies
Microenvironment and Immunology
Molecular and Cellular Pathobiology
CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer
TNRC9 Downregulates BRCA1 Expression and Promotes Breast Cancer Aggressiveness
An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity
Prevention and Epidemiology
Therapeutics, Targets, and Chemical Biology
High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma
Tumor and Stem Cell Biology
ATIP3, a Novel Prognostic Marker of Breast Cancer Patient Survival, Limits Cancer Cell Migration and Slows Metastatic Progression by Regulating Microtubule Dynamics
Letter to the Editor
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.